Ultimovacs Asa Stock Current Asset
| ULTI Stock | NOK 2.07 0.02 0.98% |
Ultimovacs ASA fundamentals help investors to digest information that contributes to Ultimovacs ASA's financial success or failures. It also enables traders to predict the movement of Ultimovacs Stock. The fundamental analysis module provides a way to measure Ultimovacs ASA's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ultimovacs ASA stock.
Ultimovacs |
Ultimovacs ASA Company Current Asset Analysis
Ultimovacs ASA's Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
In accordance with the recently published financial statements, Ultimovacs ASA has a Current Asset of 0.0. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The current asset for all Norway stocks is 100.0% higher than that of the company.
Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Ultimovacs Fundamentals
| Return On Equity | -0.33 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 3.35 B | |||
| Shares Outstanding | 34.4 M | |||
| Shares Owned By Insiders | 48.41 % | |||
| Shares Owned By Institutions | 24.83 % | |||
| Price To Book | 7.44 X | |||
| EBITDA | (161.69 M) | |||
| Net Income | (164.72 M) | |||
| Cash And Equivalents | 1.85 M | |||
| Cash Per Share | 11.95 X | |||
| Total Debt | 457 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 12.47 X | |||
| Book Value Per Share | 14.97 X | |||
| Cash Flow From Operations | (125.83 M) | |||
| Earnings Per Share | (5.09) X | |||
| Target Price | 165.0 | |||
| Number Of Employees | 23 | |||
| Beta | 1.42 | |||
| Market Capitalization | 4.11 B | |||
| Total Asset | 655.54 M | |||
| Net Asset | 655.54 M |
About Ultimovacs ASA Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ultimovacs ASA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultimovacs ASA using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultimovacs ASA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.